Piramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, ...

Indian pharma industry is capable of delivering 100 new drugs by 2047 for global markets backed by enhanced research and ...

Pankaj R Patel, Chairman of Zydus Lifesciences, envisions India delivering 100 new drugs by 2047, highlighting the importance of research, innovation, and capable human resources. He addressed myths ...

The company's Q3FY25 consolidated profit plunged 63.6 percent to Rs 3.68 crore versus Rs 10.1 crore, while revenue rose 12.5 ...

The company stated that the observations primarily pertain to procedural improvements and are not related to data integrity.

Piramal Pharma slipped 1.14% to Rs 195.40 after the US FDA issued a Form-483 with 6 observations to the company's Turbhe facility post a GMP inspection.

The observations are mainly procedural and do not indicate any data integrity issues, Piramal Pharma added in a regulatory ...

Piramal Pharma's Turbhe facility in Navi Mumbai receives six observations from U.S. FDA inspection, company preparing detailed response.

As part of the mandate, OMD will focus on improving Piramal Pharma’s market presence, brand awareness, consumer engagement, ...

Piramal Pharma has awarded its integrated media mandate to OMD India, part of Omnicom Media Group. Following a multi-round ...

OMD India has been chosen by Piramal Pharma to manage its integrated media mandate, focusing on enhancing the presence of its OTC brands. The agency’s strategic marketing and media efforts aim to ...